Literature DB >> 25633242

Overcoming adherence issues and other barriers to optimal care in gout.

Navine Nasser-Ghodsi1, Leslie R Harrold.   

Abstract

PURPOSE OF REVIEW: This review presents research published over the last year examining use of urate-lowering therapy (ULT) as well as trends over time in adherence to this class of agents. Additionally, it explores factors associated with nonadherence to ULTs for chronic gout and interventions to improve chronic gout management. RECENT
FINDINGS: New literature suggests prescriptions of ULTs for prevalent and incident gout patients remains lower than expected based on the burden of the disease in the population. Overall ULT adherence remains suboptimal, in part related to inadequate patient education and copayment costs; although one study demonstrated improvement in adherence over a 15-year study period. Finally, interventions that include patient education and medication titration based on laboratory results successfully lowered serum urate levels to less than 6 mg/dl in the majority of patients.
SUMMARY: Gout remains a prevalent disease that is poorly managed despite effective treatments. Recent research suggests that ULTs are underutilized and even when prescribed are not well adhered to. Patient-centered interventions that focus on education about pharmacologic therapy and lifestyle modifications with medication titration have resulted in a greater proportion of patients achieving recommended serum urate levels.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25633242     DOI: 10.1097/BOR.0000000000000141

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  14 in total

1.  A Pharmacist-Staffed, Virtual Gout Management Clinic for Achieving Target Serum Uric Acid Levels: A Randomized Clinical Trial.

Authors:  Robert Goldfien; Alice Pressman; Alice Jacobson; Michele Ng; Andrew Avins
Journal:  Perm J       Date:  2016-07-01

2.  Pharmacists' assessment and management of acute and chronic gout.

Authors:  Aleina Haines; Jennifer Bolt; Zack Dumont; William Semchuk
Journal:  Can Pharm J (Ott)       Date:  2018-02-09

3.  eHealth-supported decentralized multi-disciplinary care for gout involving rheumatology, pharmacy, and dietetics: proof-of-concept study.

Authors:  Alyssa Howren; Nicole W Tsao; Hyon K Choi; Kam Shojania; Alison Kydd; Russell Friesen; J Antonio Avina-Zubieta; Mary A De Vera
Journal:  Clin Rheumatol       Date:  2019-11-13       Impact factor: 2.980

4.  Key barriers to gout care: a systematic review and thematic synthesis of qualitative studies.

Authors:  Sharan K Rai; Hyon K Choi; Sally H J Choi; Anne F Townsend; Kam Shojania; Mary A De Vera
Journal:  Rheumatology (Oxford)       Date:  2018-07-01       Impact factor: 7.580

Review 5.  A systematic review of the barriers affecting medication adherence in patients with rheumatic diseases.

Authors:  Hendra Goh; Yu Heng Kwan; Yi Seah; Lian Leng Low; Warren Fong; Julian Thumboo
Journal:  Rheumatol Int       Date:  2017-07-05       Impact factor: 2.631

Review 6.  Review: Gout: A Roadmap to Approaches for Improving Global Outcomes.

Authors:  Nicola Dalbeth; Hyon K Choi; Robert Terkeltaub
Journal:  Arthritis Rheumatol       Date:  2017-01       Impact factor: 10.995

7.  Illness perception and treatment experience in patients with gout: a descriptive qualitative study.

Authors:  Qin Li; Ting Liu; Shan Zhang; Xiuxin Miao
Journal:  Clin Rheumatol       Date:  2022-01-11       Impact factor: 2.980

Review 8.  How Can We Improve Disease Education in People with Gout?

Authors:  Theodore R Fields; Adena Batterman
Journal:  Curr Rheumatol Rep       Date:  2018-03-08       Impact factor: 4.592

Review 9.  Treatment approaches and adherence to urate-lowering therapy for patients with gout.

Authors:  Thanda Aung; Gihyun Myung; John D FitzGerald
Journal:  Patient Prefer Adherence       Date:  2017-04-19       Impact factor: 2.711

10.  A cross-sectional internet-based patient survey of the management strategies for gout.

Authors:  Jasvinder A Singh; Nipam Shah; N Lawrence Edwards
Journal:  BMC Complement Altern Med       Date:  2016-03-01       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.